JPRN-jRCT2031210368已完成1 期
A PHASE 1, RANDOMIZED, DOUBLE BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETICS FOLLOWING SINGLE INTRAVENOUS DOSE OF PF-06823859 IN JAPANESE HEALTHY PARTICIPANTS
Kawai Norisuke0 个研究点目标入组 13 人开始时间: 2021年10月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 13
研究概览
简要总结
A single IV dose of PF-06823859 (300 and 900 mg) was safe and well tolerated in Japanese healthy participants evaluated in this study.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 55age old（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •1.Male and female participants must be 20 to 55 years of age, inclusive, at the time of signing the Informed Consent Document (ICD).
- •2.Participants must have 4 biologically Japanese grandparents born in Japan.
- •3.Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12 lead electrocardiogram (ECG).
- •4.Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- •5.Body Mass Index (BMI) of 17.5 to 25 kg/m2; and a total body weight >50 kg (110 lb).
- •Informed Consent:
- •6.Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
排除标准
- •Exclusion Criteria:
- •1.Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •2.History of human immunodeficiency virus (HIV) infection, hepatitis C or syphilis; positive testing for HIV, hepatitis C antibody (HCVAb) or syphilis at screening.
- •3.Infection with hepatitis b virus (HBV)
- •4.Clinically significant abnormality, including but not limited to current, active tuberculosis (TB) or previous inactive TB, general infections, heart failure or malignancy, on chest X ray performed at screening or within 12 weeks of screening.
- •5.History of autoimmune disorders.
- •6.History of allergic or anaphylactic reaction to a therapeutic drug or any components in the study intervention.
- •7.Participants with clinically significant infections, based on which the investigator judges that the participant should not be enrolled in the study, within 28 days prior to the screening visit.
- •8.Participants with a fever, based on which the investigator judges that the participant should not be enrolled in the study, within the last 7 days prior to dosing.
- •9.Participants who have evidence of tuberculosis infection.
- •*Participants who have been treated or are currently being treated for active or latent tuberculosis infection are to be excluded.
- •*Participants with a history of either untreated or inadequately treated latent or active tuberculosis infection are to be excluded.
- •10.Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg, Contact with positive case, residence, or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •11.Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.
- •12.Recent exposure to any live or attenuated live virus vaccines within 6 weeks of admission to central research unit (CRU)
- •*The use of COVID-19 vaccines (except for live or attenuated live virus vaccines) are allowed before 14 days prior to Day 1 or after discharge from CRU.
- •13.Participants who have received PF-0 6823859 or any other interferon (IFN) alpha-or IFN-beta therapy at any time in the past.
- •14.Previous administration with an investigational drug within 4 months (180 days for biologics) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
- •15.A positive urine drug test.
- •16.Screening supine blood pressure (BP) >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
- •17.Screening pulse rate (PR) >100 bpm. If the PR is greater than 100 beat per minute (bpm), the PR should be repeated 2 more times and the average of the 3 PR values should be used to determine the participant's eligibility.
- •18.Baseline standard 12 lead ECG that demonstrates clinically relevant abnormalities that may
研究者
相似试验
已完成
2 期
A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The KneeOsteoarthritis, KneeNCT00669409Pfizer83
终止
1 期
Safety and Tolerability of PF-06818883 in Healthy SubjectsHealthyNCT03020784Pfizer30
已完成
1 期
Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult SubjectsHealthyNCT03599063Pfizer63
已完成
1 期
Singe Dose Study of PF- 06946860 in Healthy Adult Japanese ParticipantsHealthyNCT03974776Pfizer8
已完成
1 期
A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562HealthyNCT01914796Pfizer39